亚盛医药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Olverembatinib Approved for Commercialization in Macau China 2024-07-08 08:55
Ascentage Pharma Received US$100 Million Option Payment from Takeda 2024-07-04 08:28
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares 2024-06-24 08:15
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda 2024-06-21 09:19
Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR 2024-06-18 12:43
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL 2024-06-18 12:23
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) 2024-06-14 21:30
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE 2024-06-11 11:25
Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% 2024-06-05 11:46
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM 2024-06-05 11:31
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety 2024-06-04 12:51
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates 2024-05-24 09:15
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress 2024-05-16 09:03
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST 2024-04-25 09:02
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting 2024-04-08 07:58
Ascentage Pharma Announces 2023 Annual Results 2024-03-27 22:30
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting 2024-03-06 08:59
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) 2024-01-17 12:10
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference 2024-01-11 11:53
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference 2024-01-02 11:58
1 2 3 4 5 9